Sulfasalazine (SSZ), an FDA‐approved first‐line drug for the treatment of rheumatoid arthritis and ulcerative colitis, has been shown to be effective in inducing ferroptosis in tumor cells by inhibiting SLC7A11.[26, 27] However, the poor water solubility and metabolic stability of SSZ limit its further clinical application in tumor therapy.[28] In vivo application of such small molecule drugs often requires repeated administration or high dosages to achieve a therapeutic effect, which can lower patients’ compliance and lead to extra adverse effects. The gene discussed is SLC7A11; the disease is neoplasm.